The growing prevalence of chronic and infectious diseases is a major driver behind the rising demand for immunodiagnostics. Moreover, the increasing need for point-of-care testing and the surge in ...

The firm reported growth across its immunodiagnostics and molecular diagnostics businesses as well as contributions from the firm's licensed technologies business.

DiaSorin targets 7% revenue growth and margin gains backed by robust fundamentals and strategic investments. Find out why ...

The firm said that its overall revenues rose 2 percent year over year and 4 percent on an organic basis with a smaller increase in its life sciences revenues.

Detailed price information for Globus Medical Inc (GMED-N) from The Globe and Mail including charting and trades.